Literature DB >> 30279000

Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: A propensity score-matched cohort.

Anita Nguyen1, Hartzell V Schaff2, Dustin Hang1, Rick A Nishimura3, Jeffrey B Geske3, Joseph A Dearani1, Brian D Lahr4, Steve R Ommen3.   

Abstract

OBJECTIVES: In patients with hypertrophic cardiomyopathy, obstruction of the left ventricular outflow tract can be relieved by surgical septal myectomy or alcohol septal ablation, but uncertainty remains regarding long-term results and comparative effectiveness of alcohol septal ablation. This study aims to compare short- and long-term outcomes of the 2 procedures.
METHODS: Between December 1998 and September 2016, 2407 patients underwent septal myectomy and 211 patients underwent alcohol septal ablation at our institution. After 2:1 propensity score matching, the study cohort included 334 patients who underwent myectomy and 167 patients who underwent alcohol septal ablation.
RESULTS: Median (interquartile range) ages of patients in the myectomy and alcohol septal ablation groups were 65 (58-71) years and 64 (56-73) years (P = .9), respectively. After intervention, median resting left ventricular outflow tract gradient at predischarge transthoracic echocardiography was 0 (0-10) mm Hg in the myectomy group (n = 288) and 21 (10-60) mm Hg in the alcohol septal ablation group (n = 63) (P < .001, tested at baseline gradients of 30 and 50 mm Hg). There were no differences in survival between the 2 groups (risk of death for alcohol septal ablation vs myectomy, hazard ratio, 1.5; 95% confidence interval, 0.9-2.6; P = .1). Survival of patients undergoing septal myectomy was better than that of an age-, sex-, and race-matched US population (82% vs 75% at 12 years, P = .01). Reintervention for left ventricular outflow tract obstruction was more likely to occur in patients who received alcohol septal ablation (hazard ratio, 33.3; 95% confidence interval, 4.4-250.6; P < .001).
CONCLUSIONS: There were no differences in survival of patients undergoing myectomy or alcohol septal ablation, but freedom from reintervention and early and late reduction of left ventricular outflow tract gradient are superior in patients undergoing septal myectomy.
Copyright © 2018 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  alcohol septal ablation; hypertrophic cardiomyopathy; myectomy

Mesh:

Substances:

Year:  2018        PMID: 30279000     DOI: 10.1016/j.jtcvs.2018.08.062

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  9 in total

Review 1.  Systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: a narrative review.

Authors:  Sarah A Guigui; Christian Torres; Esteban Escolar; Christos G Mihos
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

2.  Alcohol Septal Ablation or Septal Myectomy? An Updated Systematic Review and Meta-Analysis of Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy.

Authors:  Xifeng Zheng; Bin Yang; Haosheng Hui; Bing Lu; Yinhui Feng
Journal:  Front Cardiovasc Med       Date:  2022-05-25

3.  Surgical septal myectomy outcome for obstructive hypertrophic cardiomyopathy after alcohol septal ablation.

Authors:  Qiulan Yang; Changsheng Zhu; Hao Cui; Bing Tang; Shengwei Wang; Qinjun Yu; Shihua Zhao; Yunhu Song; Shuiyun Wang
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

4.  Mini-invasive surgical instruments in transaortic myectomy for hypertrophic obstructive cardiomyopathy: a single-center experience with 168 cases.

Authors:  Qiang Ji; Yu Lin Wang; Ye Yang; Hao Lai; Wen Jun Ding; Li Min Xia; Chun Sheng Wang
Journal:  J Cardiothorac Surg       Date:  2021-03-17       Impact factor: 1.637

5.  Endocardial Radiofrequency Ablation vs. Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy: A Systematic Review and Meta-Analysis.

Authors:  Tao Jiang; Bingyu Huang; Shengqi Huo; Lulu Monica Mageta; Junyi Guo; Jiagao Lv; Li Lin
Journal:  Front Surg       Date:  2022-04-26

6.  Periprocedural, Short-Term, and Long-Term Outcomes of Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A 20-Year Single-Center Experience.

Authors:  Umut Karabulut; Yeşim Yılmaz Can; Egemen Duygu; Dilay Karabulut; Kudret Keskin; Tuğrul Okay
Journal:  Anatol J Cardiol       Date:  2022-04       Impact factor: 1.475

7.  The Establishment of Hypertrophic Cardiomyopathy Diagnosis Model via Artificial Neural Network and Random Decision Forest Method.

Authors:  Shuanglei Li; Zekun Feng; Cangsong Xiao; Yang Wu; Weihua Ye
Journal:  Mediators Inflamm       Date:  2022-09-15       Impact factor: 4.529

8.  Treatment of Severe Left Ventricular Outflow Tract Obstruction and Mitral Regurgitation With Alcohol Septal Ablation.

Authors:  Michael Morcos; Aaron Strobel; John Messenger; Edward Gill
Journal:  CASE (Phila)       Date:  2022-08-08

9.  Targeting Alcohol Septal Ablation in Patients with Obstructive Hypertrophic Cardiomyopathy Candidates for Surgical Myectomy: Added Value of Three-Dimensional Intracoronary Myocardial Contrast Echocardiography.

Authors:  Giovanni La Canna; Iside Scarfò; Irina Arendar; Antonio Colombo; Lucia Torracca; Davide Margonato; Matteo Montorfano; Ottavio Alfieri
Journal:  J Clin Med       Date:  2021-05-17       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.